LeMaitre Vascular, Inc. $LMAT Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board grew its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.8% during the third quarter, HoldingsChannel reports. The firm owned 81,211 shares of the medical instruments supplier’s stock after buying an additional 11,092 shares during the period. Public Sector Pension Investment Board’s holdings in LeMaitre Vascular were worth $7,107,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. SG Americas Securities LLC purchased a new position in LeMaitre Vascular in the 3rd quarter valued at about $1,101,000. Vest Financial LLC boosted its holdings in LeMaitre Vascular by 60.0% in the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock valued at $4,925,000 after purchasing an additional 21,102 shares during the last quarter. First Trust Advisors LP grew its stake in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after purchasing an additional 19,447 shares during the last quarter. Finally, Congress Asset Management Co. increased its holdings in LeMaitre Vascular by 2.7% during the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after purchasing an additional 18,298 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT opened at $89.25 on Wednesday. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $85.05 and its 200 day moving average price is $88.04. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 38.47, a price-to-earnings-growth ratio of 1.94 and a beta of 0.72.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Roth Mkm reissued a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Wells Fargo & Company reduced their price target on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.